OH SCR13

Urges United States Congress, the Attorney General, and the Drug Enforcement Administration to reclassify marijuana/cannabis from Schedule I to a lower controlled substance classification

Identifies that cannabis contains over 80 active chemical components (cannabinoids) with potential therapeutic uses for epilepsy, glaucoma, PTSD, cancer, fibromyalgia, multiple sclerosis, Parkinson's disease, and amyotrophic lateral sclerosis, though rigorous clinical studies are still needed

Notes that at least 29 states plus the District of Columbia have approved comprehensive medical marijuana programs, indicating public belief in cannabis's therapeutic safety and benefits

Explains that Schedule I classification creates regulatory barriers to clinical research, including DEA registration requirements for researchers and facilities, which have likely contributed to insufficient well-controlled clinical trials

States that Schedule I status also prevents patients from obtaining health insurance coverage for medical cannabis and prevents financial institutions from providing banking services to state-authorized cannabis businesses